Protocols and Video Articles Authored by Fan Lin Translated to

Molecular understanding of KRAS- and BRAF - DiVA Portal

SATB2 plays an important role in regulating osteosarcoma stem cell-like properties and tumor growth. The combination of conventional chemotherapy and metformin may be a promising therapeutic strategy for osteosarcoma patients. 2020-11-04 · SATB2 is an immunohistochemical marker for osteoblast differentiation. Our aim was to investigate SATB2 expression in oral osteosarcoma and other bone producing oral tumors/reactive lesions to evaluate its usefulness as a diagnostic marker. Although SATB2 is not specific for osteosarcoma, it has the potential to be a useful adjunct in some settings, particularly in the distinction between hyalinized collagen and osteoid.

Satb2 osteosarcoma

CONCLUSIONS: SATB2 is a marker of osteoblastic differentiation in benign and malignant mesenchymal tumours. Although SATB2 is not specific for osteosarcoma, it has the potential to be a useful adjunct in some settings, particularly in the distinction between hyalinized collagen and osteoid. Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma June 2016 Zhonghua bing li xue za zhi Chinese journal of pathology 45(6):387-392 Low-grade osteosarcoma and fibrous dysplasia were both positive for SATB2, while desmoplastic fibroma, low-grade fibrosacoma and other fibrous tumors were negative for SATB2. Conclusions Accurate diagnosis of low-grade osteosarcoma should be based on combination of clinical presentation, imaging and histopathology, with immunohistochemistry as a diagnostic adjunct. SATB2 showed 100% sensitivity (10/10) and 60% (6/10) specificity in discriminating classic osteosarcoma from osteosarcoma mimics.

EZRIN SOM PROGNOSMARKÖR FÖR REKTALCANCER

Tissue Microarrays for Analysis of Expression - Diva Portal

Li, T., Luo Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Testföremål inkluderade Osteocalcin, Osteonectin, Osteopontin, Vim, S-100, Actin, SMA, CK, NSE, CD99, SATB2, MDM2, CDK4, Ki67 och P53, men alla Value of SATB2 Immunostaining in the Distinction Between Small Intestinal and CYC1 Silencing Sensitizes Osteosarcoma Cells to TRAIL-induced Apoptosis Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B2013Ingår i: Genome Biology, ISSN Analysis of transcript and protein overlap in a human osteosarcoma cell line2010Ingår i: BMC Genomics, ISSN 1471-2164, E-ISSN 1471-2164, Vol. 11, nr 1, s. Promotes Viability and Inhibits Apoptosis of Osteosarcoma Cells by Activating Value of SATB2 Immunostaining in the Distinction Between Small Intestinal inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Hälsa och samhälle PROGNOSTISK SIGNIFIKANS AV SATB1 OCH SATB2 Reduction of SATB2 or N-cadherin resulted in NF-κB inactivation, which led to impaired osteosarcoma sphere formation and tumor cell proliferation [54]. SATB2 is a marker of osteoblastic differentiation in benign and malignant mesenchymal tumours. Although SATB2 is not specific for osteosarcoma, it has the potential to be a useful adjunct in some settings, particularly in the distinction between hyalinized collagen and osteoid.

Stronger-intensity staining was observed in osteosarcoma (P < 0.0001). Conclusions: SATB2 is a sensitive marker for osteosarcoma; however, it is not specific, with expression being observed in other high-grade primary bone sarcomas. SATB2 was a very sensitive marker for osteosarcoma: 100% on whole slides, and 94%, including tissue micro-array (TMA) data, as reported by David and Horvai. These results are also analogous to the findings published previously by Connor and Hornick, who report a 98% sensitivity of this marker for staining osteosarcomas.
Vart skriver man adress pa kuvert

SATB2 is a highly sensitive marker for osteosarcomatous differentiation in gynecologic tract carcinosarcoma, and is also highly specific when used to differentiate osteosarcoma from chondrosarcoma and rhabdomyosarcoma elements in these tumors. SATB2 is a reliable osteoblastic marker for differential diagnosis of osteosarcoma and non-osteoid sarcoma, although with a limited role in separating osteosarcoma from non-malignant osteoblastic lesions.
Quotation sentences examples

registrera sambo skatteverket
advokatsamfundet anne ramberg
christer sjogren cover
studentportalen chalmers schema
start a company in sweden
förvaltningschef på engelska

Protocols and Video Articles Authored by Fan Lin Translated to

The sensitivity of SATB2 for osteosarcoma was 94%, and the specificity was 55%. Stronger-intensity staining was observed in osteosarcoma (P < 0.0001). Conclusions: SATB2 is a sensitive marker for osteosarcoma; however, it is not specific, with expression being observed in other high-grade primary bone sarcomas. SATB2 was a very sensitive marker for osteosarcoma: 100% on whole slides, and 94%, including tissue micro-array (TMA) data, as reported by David and Horvai.

DiVA - Sökresultat - DiVA Portal

Hälsa och samhälle PROGNOSTISK SIGNIFIKANS AV SATB1 OCH SATB2 Reduction of SATB2 or N-cadherin resulted in NF-κB inactivation, which led to impaired osteosarcoma sphere formation and tumor cell proliferation [54]. SATB2 is a marker of osteoblastic differentiation in benign and malignant mesenchymal tumours. Although SATB2 is not specific for osteosarcoma, it has the potential to be a useful adjunct in some settings, particularly in the distinction between hyalinized collagen and osteoid. SATB2 is commonly expressed in osteosarcomas. Although apparently being a valuable diagnostic marker for differentiating between small cell osteosarcoma (SCO) and other small round cell tumors of bone, for instance Ewing sarcoma family of tumors (ESFT), it has not been tested in a large series of ESFT and chondrosarcomas so far. SATB2 is a highly sensitive marker for osteosarcomatous differentiation in gynecologic tract carcinosarcoma, and is also highly specific when used to differentiate osteosarcoma from chondrosarcoma and rhabdomyosarcoma elements in these tumors. The sensitivity of SATB2 for osteosarcoma was 94%, and the specificity was 55%.

2014 May;141(5):630-8. doi: 10.1309/AJCPWW2URZ9JKQJU.